CLINICAL TRIAL FUNDING AGREEMENTClinical Trial Funding Agreement • May 16th, 2011 • Nile Therapeutics, Inc. • Pharmaceutical preparations • New York
Contract Type FiledMay 16th, 2011 Company Industry JurisdictionTHIS CLINICAL TRIAL FUNDING AGREEMENT (this “Agreement”) is entered into as of February 25, 2011 (the “Effective Date”) between NILE THERAPEUTICS, INC., a Delaware company with offices at 4 West 4th Avenue, Suite 400, San Mateo, California 99402 (“Nile”) and MEDTRONIC, INC., a Minnesota corporation with offices at 710 Medtronic Parkway, Minneapolis, Minnesota 55432, U.S.A. (“Medtronic”) (each a “Party,” collectively the “Parties”).
ContractClinical Trial Funding Agreement • May 5th, 2020 • New York
Contract Type FiledMay 5th, 2020 JurisdictionEX-10.1 2 v222336_ex10-1.htm EXHIBIT 10.1 EXHIBIT 10.1 CLINICAL TRIAL FUNDING AGREEMENT THIS CLINICAL TRIAL FUNDING AGREEMENT (this “Agreement”) is entered into as of February 25, 2011 (the “Effective Date”) between NILE THERAPEUTICS, INC., a Delaware company with offices at 4 West 4th Avenue, Suite 400, San Mateo, California 99402 (“Nile”) and MEDTRONIC, INC., a Minnesota corporation with offices at 710 Medtronic Parkway, Minneapolis, Minnesota 55432, U.S.A. (“Medtronic”) (each a “Party,” collectively the “Parties”). RECITALS WHEREAS, Nile is a company focused on the use of hybrid natriuretic peptides, including but not limited to CD-NP, as defined in the Nile Patents (“Drug”, as further defined in Section 1.1.6 below); WHEREAS, Medtronic is a leader in the business of designing, manufacturing and marketing medical devices, including medical devices for delivery of various peptides such as the Pumps and Sets (as defined in Section 2.1 below) (collectively, the “Devices”, as further de
CLINICAL TRIAL FUNDING AGREEMENTClinical Trial Funding Agreement • October 23rd, 2024 • Lumos Pharma, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledOctober 23rd, 2024 Company Industry JurisdictionThis Clinical Trial Funding Agreement (this “Agreement”) is made as of October 22, 2024 (the “Effective Date”) by and between Double Point Ventures LLC, a Delaware limited liability company (“Lender”) and Lumos Pharma, Inc., a Delaware corporation (“Borrower”).